Evaluating Contrast Sensitivity in Early and Intermediate Age-Related Macular Degeneration With the Quick Contrast...

Area of Science:

• Ophthalmology
• Vision Science

Background:

• Age-related macular degeneration (AMD) is a leading cause of vision loss.
• Assessing functional vision changes in early and intermediate AMD is crucial for monitoring disease progression and treatment efficacy.
• Current methods like Pelli-Robson charts and visual acuity (VA) testing may not detect subtle functional deficits in early AMD stages.

Purpose of the Study:

• To describe, validate, and compare contrast sensitivity functions (CSFs) using the novel quick CSF (qCSF) method.
• To evaluate the qCSF method's ability to detect functional differences in patients with early and intermediate age-related macular degeneration (eAMD and iAMD) compared to healthy controls.
• To identify novel qCSF-derived metrics for use in AMD therapeutic trials.

Main Methods:

• Cross-sectional analysis of baseline data from the Multimodal Functional and Structural Visual System Characterization (MUMOVI) study.
• Contrast sensitivity (CS) and VA were measured using the quick CSF (qCSF) method with a manifold contrast vision meter.
• Analysis included CS levels at various spatial frequencies (1-18 cycles per degree), area underneath the logarithmic CSF (AULCSF), and contrast acuity (CA).

Main Results:

• Ninety-four eyes from 94 patients (13 eAMD, 33 iAMD, 48 controls) were analyzed.
• Significant differences between eAMD and iAMD were found for CS at 1 CPD (P=0.006) and 1.5 CPD (P=0.01).
• A correlation between smoking duration and CS at 1 and 1.5 CPD was observed in AMD patients.

Conclusions:

• The qCSF method allows rapid measurement of the entire CSF, suitable for clinical integration.
• qCSF-derived metrics can detect subtle functional vision differences between AMD stages that standard tests may miss.
• This study provides novel qCSF-derived candidate metrics for evaluating treatments in AMD clinical trials.